First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia Our study demonstrated that ...
Gift 5 articles to anyone you choose each month when you subscribe. Listed mortgage company RHG, formally RAMS Mortgage Corp, has engaged with suitor Resimac and opened the door to a period of due ...
On Monday, RHG directors announced they had agreed to accept the latest bid of 48 cents per share as well as a three-cent-per share dividend, with total payments of 51 cents per share. The total puts ...
TWO days after the RHG board recommended a takeover deal to investors, the company has received a rival bid for the mortgage business. Pepper has put an offer to the RHG board which would see ...
In July 2007, UBS arranged the sale by John Kinghorn and Greg Jones of about 80 per cent of their respective shareholdings in RHG for $2.50 per share, raising gross proceeds of $695.3 million. One of ...
Pepper, which typically provides low-doc loans, yesterday unveiled an offer of 46c a share for RHG, which it claimed was "superior" to a bid by rival non-bank Resimac and dealmaker Trevor Loewensohn.
John Kinghorn ’s RHG has resolved to make its first dividend payment after the emphatic rejection of the company’s buyback proposal by shareholders yesterday. Management of the former non-bank lender, ...
Non-bank lender Resimac has made a bid to acquire the remnants of mortgage firm RAMS in a joint proposal with former Babcock & Brown banker Trevor Loewensohn. The conditional proposal values the ...
First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia We conducted a phase II, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results